Results indicated that THY1 was significantly upregulated in breast cancer, cholangiocarcinoma (CHOL), colon adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, LUSC, prostate adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma, and thyroid carcinoma. Here, THY1 is linked to rectum adenocarcinoma.